Robotic Surgery May Allow for Quicker Procedures With Less Radiation

Commentary
Video

The Epione robot may help less experienced surgeons carry out complex cases with a high level of accuracy, says Govindarajan Narayanan, MD.

Govindarajan Narayanan, MD, explained that the advent of the Epione surgical robot may be a precursor to future technological advancements in the world of surgical oncology, including the potential for practices to treat patients remotely and with less radiation.

In an interview with CancerNetwork®, Narayanan, a professor of Radiology and an interventional radiologist at Miami Cardiac and Vascular Institute and the chief of Interventional Oncology at Miami Cancer Institute, Baptist Health South Florida, described how Epione “levels the playing field” by making the surgical process quicker while potentially increasing the availability of physicians who can offer surgery to patients across centers. He said that practices in other countries have already been operating the surgical robot remotely, which would allow patients to undergo surgery at treatment centers even if a practicing physician is not there in-person.

Developers designed the Epione robot to streamline several probe procedures, thereby making treatment of large tumors via microwave ablation, cryoablation, irreversible electroporation, and other strategies more predictable.

Transcript:

[Epione] levels the playing field. It can bring less experienced users to do these procedures with a higher level of accuracy. That may improve the availability of physicians who can offer these treatments in multiple centers.

We are at the beginning of an exciting technology that’s being introduced in the space of image-guided ablation. In other countries, they’re using these robotic devices remotely; I feel that we will eventually get to the point where the science would allow us to operate on patients in remote locations, thereby improving access to these cutting-edge technologies in different institutions where they may not have the physician stationed there. [I see Epione] being able to help less experienced physicians do more complex cases with less radiation, quicker procedure times, and [the potential for] remote access. That is where I see this [technology] going.

Reference

Epione. Quantum Surgical. Accessed November 7, 2023. https://shorturl.at/dqyL6

Recent Videos
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
Related Content